Shimin Hu, M.D., Ph.D.
Department of Hematopathology, Division of Pathology and Laboratory Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1998 | University of Michigan, Ann Arbor, MI, USA, PHD, Molecular and Cellular Pathology |
| 1993 | Peking University, Beijing, CHN, MD, Medicine |
Postgraduate Training
| 2011-2013 | Clinical Fellowship, Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2008-2011 | Clinical Residency, Anatomic and Clinical Pathology, Hartford Hospital, Hartford, CT |
| 2007-2008 | Clinical Residency, University of Toledo, Toledo, OH |
Board Certifications
| 2012 | American Board of Pathology, Hematology |
| 2011 | American Board of Pathology, Anatomic and Clinical Pathology |
Selected Publications
Peer-Reviewed Articles
- Kurt H, Zheng L, Kantarjian HM, Tang G, Ravandi-Kashani F, Garcia-Manero G, Gong Z, Amin HM, Konoplev SN, Routbort MJ, Han X, Wang W, Medeiros LJ, Hu S. Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Mod Pathol, 2018.
- Gong Z, Medeiros LJ, Cortes JE, Chen Z, Zheng L, Li Y, Bai S, Lin P, Miranda RN, Jorgensen LJ, McDonnell TJ, Wang W, Kantarjian H, Hu S. Cytogenetics-based risk prediction of blastic transformation of CML treated with tyrosine kinase inhibitors. Blood Adv 1(26):2541-2552, 2017.
- Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W, Tang G, Loghavi S, Luthra R, Yang W, Kantarjian H, Hu S.. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J 7(7):e583, 2017. PMID: 28708130.
- Chen Z, Shao C, Wang W, Zuo Z, Mou X, Hu SJ, DiGiuseppe JA, Zu Y, Medeiros LJ, Hu S.. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 31(3):585-592, 2017. e-Pub 2016. PMID: 27560111.
- Chen Z, Medeiros LJ, Kantarjian HM, Zheng L, Gong Z, Patel KP, Xiong H, Wang W, Cortes JE, Hu S.. Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. Blood Cancer J 7(2):e521, 2017. PMID: 28157214.
- Chen Z, Cortes JE, Jorgensen JL, Wang W, Yin CC, You MJ, Jabbour E, Kantarjian HM, Medeiros LJ, Hu S.. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 30(7):1606-1609, 2016. e-Pub 2016. PMID: 26837843.
- Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian HM, Medeiros LJ, Hu S.. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 127(22):2742-50, 2016. e-Pub 2016. PMID: 27006386.
- Chen Z, Wang W, Cortes JE, Liu E, Miranda RN, Zhao C, Yuan J, Lu, X, Yang W, Dadfarnia M, Kantarjian HM, Medeiros LJ, Hu S.. Differential clinical and prognostic impact of myeloid sarcoma versus medullary myeloid blast phase in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer J 6(e418), 2016. PMID: 27152845.
- Wang W, Cortes JE, Lin P, Khoury JD, Ai D, Tang Z, Tang G, Jorgensen JL, Medeiros LJ, Hu S.. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia 29(11):2263-6, 2015. e-Pub 2015. PMID: 25931274.
- Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu S.. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood 126(14):1699-706, 2015. PMID: 26243778.
- Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH.. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121(20):4021-31; quiz 4250, 2013. e-Pub 2013. PMID: 23449635.
- Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH.. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121(14):2715-24, 2013. e-Pub 2013. PMID: 23343832.